LIGAND PHARMACEUTICALS INCORPORATED Deferred Tax Assets, Net of Valuation Allowance
LIGAND PHARMACEUTICALS INCORPORATED (LGNYZ) had Deferred Tax Assets, Net of Valuation Allowance of $58.44 million as of 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance
us-gaap:DeferredTaxAssetsNet · last filed 2026-02-27
- 2025-12-31: Deferred Tax Assets, Net of Valuation Allowance $58.44M.
- 2024-12-31: Deferred Tax Assets, Net of Valuation Allowance $40.69M.
- 2023-12-31: Deferred Tax Assets, Net of Valuation Allowance $46.06M.
- 2022-12-31: Deferred Tax Assets, Net of Valuation Allowance $53.50M.
| Period end | Deferred Tax Assets, Net of Valuation Allowance | Deferred Tax Assets, Net of Valuation Allowance as first filed |
|---|---|---|
| 2025-12-31 | $58.44M 10-K · filed 2026-02-27 | |
| 2024-12-31 | $40.69M 10-K · filed 2026-02-27 | |
| 2023-12-31 | $46.06M 10-K · filed 2025-02-28 | |
| 2022-12-31 | $53.50M 10-K · filed 2024-02-29 | |
| 2021-12-31 | $77.18M 10-K · filed 2023-02-28 | $86.91M 10-K · filed 2022-02-28 |
| 2020-12-31 | $84.03M 10-K · filed 2022-02-28 | |
| 2019-12-31 | $44.38M 10-K · filed 2021-02-24 | $42.78M 10-K · filed 2020-02-27 |
| 2018-12-31 | $98.49M 10-K · filed 2020-02-27 | |
| 2017-12-31 | $136.05M 10-K · filed 2019-02-28 | |
| 2016-12-31 | $197.73M 10-K · filed 2018-03-01 | |
| 2015-12-31 | $208.57M 10-K · filed 2017-02-28 | $236.05M 10-K · filed 2016-02-26 |
| 2014-12-31 | $15.98M 10-K · filed 2016-11-14 | $14.81M 10-K · filed 2014-12-01 |
| 2013-12-31 | $14.81M 10-K · filed 2015-02-23 | |
| 2012-12-31 | $15.14M 10-K/A · filed 2014-12-12 | |
| 2011-12-31 | $17.88M 10-K · filed 2013-03-14 |